New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago

Malvika Kaul1,2,3, Preeti Gupta1,2, Salil Kalra1,2, Jessica Gardner3, Howard S. Gordon2,3,4 and Israel Rubinstein1,2,3

1Division of Pulmonary, Critical Care, Sleep and Allergy Medicine, University of Illinois, Chicago, IL, USA. 2Medical Services, Jesse Brown VA Medical Center Chicago, Chicago, IL, USA. 3Research Services, Jesse Brown VA Medical Center Chicago, Chicago, IL, USA. 4Division of Academic Internal Medicine, Dept of Medicine, University of Illinois, Chicago, IL, USA.

Corresponding author: Malvika Kaul (mkaul2@uic.edu)

Shareable abstract (@ERSpublications)
A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental O2 therapy among survivors of COVID19 hospitalisation with persistent hypoxaemia upon discharge; hence, proper monitoring and evaluation are recommended https://bit.ly/3HRlfxE

Cite this article as: Kaul M, Gupta P, Kalra S, et al. New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago. ERJ Open Res 2022; 8: 00577-2021 [DOI: 10.1183/23120541.00577-2021].

Abstract

Background A knowledge gap exists in understanding the beneficial use and duration of domiciliary supplemental oxygen (DSO) therapy among survivors of coronavirus disease 2019 (COVID-19) hospitalisations with persistent hypoxaemia upon discharge. The purpose of this single centre study was to begin to address this issue.

Methods In this retrospective study we report features of US military veterans residing in metropolitan Chicago with no prior DSO therapy who survived COVID-19 hospitalisation, were discharged on DSO and were followed for 6 months.

Results We found that the majority of the 65 elderly patients (median age, 70 years), predominantly obese Black males, who survived COVID-19 hospitalisations at the Jesse Brown VA Medical Center and were discharged on DSO did not undergo a formal 6-min walk test (6MWT) to re-assess ongoing ambulatory supplemental oxygen requirements (46 patients or 71%). Nonetheless, DSO therapy was discontinued in most patients predominantly within 8 weeks of hospital discharge (34 patients, 52%). In addition, a large proportion of patients, obese Black people in particular, who survived COVID-19 hospitalisations and were treated with DSO for at least 8 weeks thereafter developed post-acute sequelae of COVID-19 infection (PASC) (30 patients, 46%).

Conclusions Given these findings, we recommend that healthcare providers be appraised about proper monitoring and evaluation, including timely performance of 6MWT, of patients who survived COVID-19 hospitalisations and were treated with DSO for persistent hypoxaemia upon discharge. Whether obese Black males who survived COVID-19 hospitalisations and are treated with DSO thereafter have an elevated risk in developing PASC remains to be determined in larger, prospective studies.

Introduction

It is well-established that long-term, domiciliary supplemental oxygen therapy is beneficial in some patients with distinct lung diseases [1–5]. To that end, a knowledge gap exists in understanding the attributes of domiciliary supplemental oxygen therapy among survivors of coronavirus disease 2019 (COVID-19) hospitalisations who were discharged with domiciliary supplemental oxygen therapy due to persistent hypoxaemia [6–9].

For instance, CHOPRA et al. [10] reported that only 32 out of 1250 survivors of COVID-19 hospitalisations in the State of Michigan (2.6%) required new domiciliary supplemental oxygen 60 days after discharge. BANERJEE et al. [11] found low 30-day all-cause mortality (1.3%) and hospital readmission rate (8.5%) among 621 patients with acute COVID-19 illness in the USA who were discharged from the hospital with
supplemental oxygen. However, the median follow-up of these patients was only 26 days thereby precluding assessment of long-term, domiciliary supplemental oxygen therapy. Moreover, whether these patients had new supplemental oxygen requirements upon hospital discharge was not addressed in this study. Finally, Shah et al. [7] did not report new supplemental oxygen requirements among 60 patients prospectively followed for 12 weeks for respiratory outcomes after COVID-19 hospitalisations in Vancouver, Canada.

Given the paucity of studies addressing clinical management of new domiciliary supplemental oxygen therapy among survivors of COVID-19 hospitalisations with persistent hypoxaemia, the purpose of this single centre, retrospective study was to begin to address this knowledge gap. Here we report features of US military veterans residing in metropolitan Chicago with no prior domiciliary supplemental oxygen therapy who survived COVID-19 hospitalisations, were discharged with domiciliary supplemental oxygen therapy due to persistent hypoxaemia and were followed for 6 months.

Methods
A retrospective review of VA Computerised Patient Record System (CPRS) of 285 veterans hospitalised at and discharged from the Jesse Brown VA Medical Center (JBVAMC) in Chicago, Illinois, between March 2020 and February 2021 for reverse transcriptase PCR-positive, acute COVID-19 illness was performed. These patients were identified using the JBVAMC registry of all patients tested at the JBVAMC for COVID-19 during this period. JBVAMC is a tertiary academic healthcare centre located in the near West Side neighbourhood of Chicago. It consists of a 220-bed facility (158 acute care beds) and four community-based outpatient clinics. The medical centre provides care to ~49,000 veterans who reside in the City of Chicago and Cook County, Illinois, and in six counties in northwestern Indiana. It is a major teaching affiliate of Feinberg School of Medicine of Northwestern University and University of Illinois College of Medicine at Chicago. The study was approved by JBVAMC Institutional Review Board.

Patient data abstracted from CPRS comprised of demographics, comorbidities and hospital course. After hospital discharge, data collected from CPRS included flow rate and duration of domiciliary supplemental oxygen therapy, follow-up virtual and/or face-to-face clinic visits with healthcare providers, unscheduled visits to the emergency department, hospitalisations and documentation of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) symptoms (defined below) by healthcare providers at day 30, week 8, and from 8 weeks to 6 months thereafter. In each patient, the need for domiciliary supplemental oxygen upon hospital discharge was assessed by detailed medical history, clinical examination and pulse oximetry <88% at rest or during ambulation. Domiciliary supplemental oxygen, ancillary equipment, technical support, education, educational resources and regular home visits were provided to eligible patients by a single commercial vendor contracted by JBVAMC in accordance with Veterans Health Administration Directive 1173.13. Post-acute sequelae of SARS-CoV-2 infection was defined as symptoms and/or abnormalities associated with SARS-CoV-2 infection (e.g., “brain fog” and shortness of breath) that persisted beyond 4 weeks of hospital discharge that were not present prior to the onset of SARS-CoV-2 and were not attributable to alternative diagnoses [12–16].

Descriptive statistics were used for primary analysis and are reported as mean±SD, median with interquartile range (IQR) and per cent where appropriate.

Results
Clinical course after hospital discharge
We found that 65 of 285 patients (23%) with acute COVID-19 illness were discharged from JBVAMC with new domiciliary supplemental oxygen therapy during the study period. None had domiciliary supplemental oxygen therapy prescribed before contracting COVID-19 infection. Patient characteristics are depicted in table 1. They were elderly (median age, 70), obese, predominantly Black (69%) men (94%) (table 1). 68% had a history of smoking, and 19% reported smoking tobacco at the time of hospital admission. The predominant underlying comorbidities among this cohort were hypertension (83%), hyperlipidaemia (62%), diabetes mellitus Type 2 (49%), obstructive sleep apnoea (40%), COPD (29%) and gastro-oesophageal reflux disease (25%) (table 1).

During hospitalisation, two patients (3%) required invasive mechanical ventilation, seven (10%) noninvasive ventilation and 19 (29%) high-flow supplemental oxygen delivered with nasal cannulae. The remaining 37 patients required supplemental oxygen at flow rates ≤5 L·min⁻¹ or none. Mean length of hospital stay was 11±10 days. All 65 patients were discharged from JBVAMC with a median supplemental oxygen flow rate of 2 L·min⁻¹ (IQR, 2–2 L·min⁻¹) either continually or during exertion (table 1).
All 65 patients were followed for 6 months after hospital discharge. Within 30 days of hospital discharge, 50 patients (77%) had at least one follow-up clinic virtual or face-to-face visit with a primary care physician (PCP) at JBVAMC. 18 patients (28%) had at least one unscheduled visit to the emergency department, and nine (14%) had at least one all-cause readmission to JBVAMC. No deaths were reported during this time frame (table 2).

Eight weeks after hospital discharge, 60 patients (92%) had at least one follow-up virtual or face-to-face clinic visit with a PCP at JBVAMC. 23 patients (35%) had at least one unscheduled visit to the emergency department, and 13 (20%) had at least one all-cause hospitalisation at JBVAMC during this time frame. Importantly, 43 patients (66%) reported PASC (table 2). No deaths were reported during this observation period.

From 8 weeks to 6 months after hospital discharge, 51 patients (79%) had at least one follow-up virtual or face-to-face clinic visit with a PCP, 31 (48%) had at least one unscheduled visit to the emergency department and nine (14%) had at least one all-cause hospitalisation at JBVAMC. At this time point, 17 patients (26%) had PASC-related visits to the emergency department or readmission at JBVAMC, and 29 (45%) had PASC.

---

**TABLE 1 Characteristics of patients discharged on new supplemental oxygen therapy (n=65)**

| Baseline characteristics | 70 (62–74) |
|--------------------------|------------|
| Age years, median (IQR)  |            |
| Sex                      |            |
| Male                     | 61 (94)    |
| Female                   | 4 (6)      |
| Race                     |            |
| African American         | 45 (69)    |
| Caucasian                | 16 (25)    |
| Other                    | 4 (6)      |
| Smoking history          |            |
| Current smoker           | 12 (19)    |
| Previous smoker          | 32 (49)    |
| Unknown                  | 21 (32)    |
| Underlying comorbidities |            |
| Hypertension             | 54 (83)    |
| Hyperlipidaemia          | 40 (62)    |
| Obesity (BMI ⩾30 kg·m⁻²) | 38 (59)    |
| Diabetes mellitus Type 2 | 32 (49)    |
| Obstructive sleep apnoea | 26 (40)    |
| Chronic obstructive pulmonary disease | 19 (29) |
| Coronary artery disease  | 10 (15)    |
| Gastro-oesophageal reflux disease | 16 (25) |
| Chronic kidney disease   | 15 (23)    |
| Non-lung cancer          | 9 (14)     |
| Asthma                   | 5 (8)      |
| HFrEF                    | 4 (6)      |
| HfPcEF                   | 4 (6)      |
| History of venous thromboembolism | 4 (6) |
| Cirrhosis                | 3 (5)      |
| Interstitial lung disease| 2 (3)      |
| Lung cancer              | 1 (2)      |
| Solid organ transplant   | 1 (2)      |
| Sarcoidosis              | 1 (2)      |
| Connective tissue disease| 1 (2)      |
| Index hospitalisation    |            |
| Invasive mechanical ventilation | 2 (3) |
| Noninvasive ventilation  | 7 (10)     |
| High-flow nasal cannula  | 19 (29)    |
| Length of stay days (mean±SD) | 11±10 |
| Supplemental oxygen on discharge L·min⁻¹, median (IQR) | 2 (2–2) |

Data are presented as n (%) unless otherwise stated. IQR: interquartile range; BMI: body mass index; HFrEF: heart failure with reduced ejection fraction; HfPcEF: heart failure with preserved ejection fraction.
reported to their PCPs (table 2). Two patients (3%) died during follow-up; both did not require high-flow nasal cannula or noninvasive or invasive ventilation during their index hospitalisation (table 2).

New domiciliary supplemental oxygen therapy
A 6-min walk test (6MWT) to assess ongoing requirement for domiciliary supplemental oxygen therapy was only performed in four patients prior to 8 weeks and 15 patients (23%) after 8 weeks from hospital discharge. Nonetheless, domiciliary supplemental oxygen therapy was discontinued in 34 patients (52%) within 8 weeks of hospital discharge (table 2), six of which had discontinuation of supplemental oxygen within 4 weeks of discharge. The number of patient referrals to the pulmonary clinic at JBVAMC during the 6-month observation period was <50% during each study period (table 2).

30 patients (46%), predominantly obese Black males with hypertension and hyperlipidaemia, who were discharged with domiciliary supplemental oxygen therapy reported PASC for at least 8 weeks after hospital discharge-reported PASC (table 3). Out of these, only 10 patients (33%) had documented supplemental oxygen discontinued by self or provider during the study period (from 4 weeks to 6 months of index COVID-19 hospitalisation). None required invasive mechanical ventilation during hospitalisation. 13 patients required supplemental high-flow oxygen therapy through nasal cannula or noninvasive ventilation. Nine patients (30%) were readmitted to JBVAMC within 30 days of hospital discharge, while 10 (33%) were readmitted within 8 weeks. Two patients who were treated with domiciliary supplemental oxygen and subsequently diagnosed with PASC died during follow-up (table 3).

Discussion
There are three new findings of this study. We found that the majority of elderly patients, predominantly obese Black males, residing in metropolitan Chicago who survived COVID-19 hospitalisations at JBVAMC, discharged on domiciliary supplemental oxygen due to persistent hypoxaemia, and followed for 6 months did not undergo 6MWT to re-assess the need for domiciliary supplemental oxygen. Nonetheless, oxygen therapy was discontinued in most patients predominantly within 8 weeks of hospital discharge. During this time frame, 92% of patients had at least one follow-up virtual or face-to-face clinic visit with a PCP. In addition, a large proportion of patients, obese Black men in particular, who survived COVID-19 hospitalisations and were treated with domiciliary supplemental oxygen for at least 8 weeks thereafter developed PASC. Given these data, we recommend that healthcare providers be appraised about proper monitoring and evaluation, including timely performance of 6MWT, of patients who survived COVID-19 hospitalisations and were treated with domiciliary supplemental oxygen for persistent hypoxaemia upon discharge. Whether obese Black males who survived COVID-19 hospitalisations and were treated with domiciliary supplemental oxygen thereafter are more prone to developing PASC remains to be determined in larger, prospective studies.

### Table 2. Patient outcomes after hospital discharge (n=65)

| Outcome                        | At 8 weeks n (%) | 8 weeks to 6 months n (%) |
|-------------------------------|------------------|---------------------------|
|                               | Within 30 days   | 30 days to 8 weeks        |
| Healthcare utilisation and mortality |                  |                           |
| Primary care provider visits  | 50 (77)          | 60 (92)                   |
| Emergency department visits   | 18 (28)          | 23 (35)                   |
| Readmissions (all causes)     | 9 (14)           | 13 (20)                   |
| Mortality (all causes)        | 0 (0)            | 0 (0)                     |
| Supplemental oxygen reassessment and utilisation |                  |                           |
| 6-min walk test               | 4 (6)            | 15 (23)                   |
| Pulmonary clinic visit        | 26 (40)          | 15 (23)                   |
| Supplemental oxygen discontinued | 34 (52)        | 10 (15)                   |
| Insufficient documentation    | 0                | 6 (9)                     |
| PASC                          |                  |                           |
| Total with PASC (reported at PCP or ED visit) | nn (%)          | 30 (46)                   |
| Reported during ED visits/readmissions | 43 (66)       | 17 (26)                   |
| Reported to primary care provider | 39 (60)       | 29 (45)                   |

PASC: post-acute sequelae of COVID-19 infection; PCP: primary care physician; ED: emergency department; COVID-19: coronavirus disease 2019; nn (%?): aggregate not assessed for the group at 8 weeks.
A recent large cohort study of US military veterans who survived COVID-19 hospitalisations found higher risk of persistent hypoxaemia 4 months after hospital discharge in comparison to veterans who survived influenza hospitalisations [14]. Because COVID-19 is a new disease entity, dedicated practice guidelines for managing domiciliary supplemental oxygen therapy in survivors of COVID-19 hospitalisations with persistent hypoxaemia have not been published as of yet [8, 17]. For instance, AYOUBKHANI et al. [16] recently reported on 47780 patients with COVID-19 who were discharged from hospitals in the UK and followed for a mean of 140 days. Although the investigators found an increased rate of respiratory dysfunction in these patients compared with a matched control group, they did not address new domiciliary

| TABLE 3 Characteristics of patients who reported PASC ≥8 weeks after hospital discharge (n=30) |
|---------------------------------|----------------------------------------------------------------------------------|
| Characteristics of patients with PASC                                                                 |
| Age years, median (IQR)          | 70 (63–76)                                                                       |
| Sex                             | Male 30 (100)                                                                   |
| Race                            | African American 21 (70)                                                        |
|                                | Caucasian 6 (20)                                                                |
|                                | Others 3 (10)                                                                   |
| Smoking history                 | Current smoker 8 (26)                                                            |
|                                | Previous smoker 17 (56)                                                          |
|                                | Unknown 5 (18)                                                                  |
| Comorbid conditions             | Hypertension 25 (83)                                                            |
|                                | Hyperlipidaemia 20 (66)                                                         |
|                                | Obesity (BMI ≥30 kg·m⁻²)                                                        |
|                                | Diabetes mellitus Type 2 14 (46)                                                 |
|                                | Obstructive sleep apnoea 12 (40)                                                |
|                                | Chronic obstructive pulmonary disease 10 (33)                                    |
|                                | Gastro-oesophageal reflux disease 10 (33)                                       |
|                                | Coronary artery disease 6 (20)                                                   |
|                                | Chronic kidney disease 5 (16)                                                    |
|                                | Non-lung cancer 4 (13)                                                           |
|                                | HFrEF 3 (10)                                                                    |
|                                | Cirrhosis 3 (10)                                                                |
|                                | Asthma 2 (6)                                                                    |
|                                | History of venous thromboembolism 2 (6)                                          |
|                                | HFrEF 2 (6)                                                                     |
|                                | Interstitial lung disease 1 (3)                                                  |
|                                | Lung cancer 1 (3)                                                               |
|                                | Solid organ transplant 1 (3)                                                     |
|                                | Sarcoidosis 1 (3)                                                               |
|                                | Connective tissue disease 1 (3)                                                  |
| Index hospitalisation           | Mean length of stay days (mean±sd) 11±10                                         |
| Supplemental oxygen therapy     | In-hospital                                                                      |
|                                | Noninvasive ventilation 3 (10)                                                   |
|                                | High-flow nasal canula 10 (33)                                                   |
|                                | Invasive mechanical ventilation 0                                               |
|                                | Flow rate (at hospital discharge) L·min⁻¹, mean (IQR) 2 (2–3)                   |
| Readmission and mortality outcomes | Readmission within                                                               |
|                                | 30 days (all-cause) 9 (30)                                                       |
|                                | 30 days to 8 weeks (all-cause) 10 (33)                                            |
|                                | 8 weeks to 6 months (all-cause) 5 (16)                                            |
|                                | Mortality (all-cause) 2 (6)                                                      |

Data are presented as n (%) unless otherwise stated. PASC: post-acute sequelae of COVID-19 infection; IQR: interquartile range; BMI: body mass index; HFrEF: heart failure with reduced ejection fraction; HFrEF: heart failure with preserved ejection fraction; COVID-19: coronavirus disease 2019. #: median time to death 130 days.
supplemental oxygen therapy among them. Similar omissions are noted in recent large cohort studies of patients with COVID-19 conducted in China and Switzerland [9, 18].

A prospective, single site observational cohort study of 152 patients who survived COVID-19 hospitalisation in New York City, NY and were followed for a median of 37 days found that 52 (34%) had a new supplemental oxygen requirement at discharge [19]. 20 patients still required 1–2 L·min\(^{-1}\) supplemental oxygen during the ensuing short follow-up. These figures are similar to those reported in the current study. Finally, Loering et al. [20] reported new domiciliary oxygen therapy in 41 out of 310 patients (13.2%) hospitalised for COVID-19 in an academic medical centre in Atlanta, GA within 30 days of discharge. However, no additional details about ongoing need for supplemental oxygen after this time point were provided. Taken together, these studies highlight the urgent need to establish a practice guideline for domiciliary supplemental oxygen therapy in survivors of COVID-19 hospitalisations with persistent hypoxaemia after discharge.

The limitations of our retrospective study are obvious, including single medical centre in metropolitan Chicago, small sample size, male predominance and no matched control group. This limits the generalizability of our observations and limits our ability to elucidate the possible roles of comorbid conditions and tobacco smoking as risk factors for developing PASC. We also recognise that most outpatient encounters reported in this study occurred remotely using telehealth-enabled technology due to the ongoing COVID-19 pandemic in metropolitan Chicago. This may have limited formal health assessment, including ongoing need for supplemental oxygen, of our patients. Nonetheless, we have addressed this issue, in part, by extending the study period to 6 months after hospital discharge thereby facilitating patient access to primary care providers at JBVAMC. In addition, interrogation of CPRS, JBVAMC-specific robust electronic health record, enabled us to capture all post-discharge clinic and virtual visits of our patients along with complications observed during this time frame. Moreover, the commercial vendor contracted by JBVAMC provided regular delivery of oxygen tanks or concentrators and supplies along with home visits to patients’ residences thereby promoting adherence with prescribed supplemental oxygen therapy.

Finally, the results of this study underscore the need to develop, implement and disseminate cost-effective, wireless, telehealth-enabled technologies to monitor patients who survived COVID-19 hospitalisations with limited access to clinic visits after discharge for actual need for domiciliary supplemental oxygen therapy.

In summary, we recommend that healthcare providers be appraised about proper monitoring and evaluation, including timely performance of 6MWT, of patients who survived COVID-19 hospitalisations and were treated with domiciliary supplemental oxygen for persistent hypoxaemia upon discharge. Whether obese Black males who survived COVID-19 hospitalisations and treated with domiciliary supplemental oxygen thereafter are more prone to develop PASC and if use of domiciliary supplemental oxygen is associated with development or persistence of PASC remains to be determined in larger, prospective studies.

Provenance: Submitted article, peer reviewed.

Conflict of interest: None of the authors has declared any conflict of interest that may arise from being named as an author of this manuscript.

Support statement: This work was supported, in part, by grants I50 CU000179-01 (to I. Rubinstein) and IIR 12–050 (to H.S. Gordon) from the US Dept of Veterans Affairs, and by grant ILHU0049-19 from the US Dept of Housing and Urban Development (I. Rubinstein). The views expressed in this article are those of the authors, and do not necessarily reflect the position or policy of the Depts of Veterans Affairs or Housing and Urban Development, or the US Government. Funding information for this article has been deposited with the Crossref Funder Registry.

References
1 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391–398.
2 Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, Blackford AL, et al. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med 2016; 375: 1617–1627.
3 Jacobs SS, Lederer DJ, Garvey CM, et al. Optimizing home oxygen therapy. An official American Thoracic Society Workshop Report. Ann Am Thorac Soc 2018; 15: 1369–1381.

https://doi.org/10.1183/23120541.00577-2021
Lacasse Y, Tan AM, Maltais F, et al. Home oxygen in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2018; 197: 1254–1264.

Jacobs SS, Krishnan JA, Lederer DJ, et al. Home oxygen therapy for adults with chronic lung disease. An official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med* 2020; 202: e121–e141. Erratum in: *Am J Respir Crit Care Med* 2021; 203: 1045–1046.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020; 323: 1239–1242.

Shah AS, Wong AW, Hague CJ, et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. *Thorax* 2021; 76: 402–404.

Abdelnabi M, Leelaviwat N, Eshak N, et al. COVID-19 discharge and follow-up recommendations. *Proc (Bayl Univ Med Cent)* 2020; 34: 73–75.

Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021; 397: 220–232.

Chopra V, Flanders SA, O’Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID-19. *Ann Intern Med* 2021; 174: 576–578.

Banerjee J, Canamar CP, Voyageur C, et al. Mortality and readmission rates among patients with COVID-19 after discharge from acute care setting with supplemental oxygen. *JAMA Netw Open* 2021; 4: e213990.

World Health Organization. A clinical case definition of post-COVID-19 condition by a Delphi consensus. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Date last accessed: 12 December 2021. Date last updated: 6 October 2021.

Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med* 2021; 27: 601–615.

Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature* 2021; 594: 259–264.

Hirschtick JL, Titus AR, Slocum E, et al. Population-based estimates of post-acute sequelae of SARS-CoV-2 infection (PASC) prevalence and characteristics. *Clin Infect Dis* 2021; 73: 2055–2064.

Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ* 2021; 372: n693.

Sardesai I, Grover J, Garg M, et al. Short-term home oxygen therapy for COVID-19 patients: the COVID-HOT algorithm. *J Family Med Prim Care* 2020; 9: 3209–3219.

Weerahandi H, Hochman KA, Simon E, et al. Post-discharge health status and symptoms in patients with severe COVID-19. *J Gen Intern Med* 2021; 36: 738–745.

Loerinc LB, Scheel AM, Evans ST, et al. Discharge characteristics and care transitions of hospitalized patients with COVID-19. *Healthc (Amst)* 2021; 9: 100512.